Summary
Global Markets Direct’s, ‘Neurofibromatoses Type II - Pipeline Review, H1 2016’, provides an overview of the Neurofibromatoses Type II pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Neurofibromatoses Type II, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neurofibromatoses Type II and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type II
- The report reviews pipeline therapeutics for Neurofibromatoses Type II by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neurofibromatoses Type II therapeutics and enlists all their major and minor projects
- The report assesses Neurofibromatoses Type II therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neurofibromatoses Type II
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neurofibromatoses Type II
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neurofibromatoses Type II pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Arno Therapeutics, Inc.
CalAsia Pharmaceuticals, Inc.
Lixte Biotechnology Holdings, Inc.
Novartis AG
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Neurofibromatoses Type II Overview 6
Therapeutics Development 7
Pipeline Products for Neurofibromatoses Type II - Overview 7
Pipeline Products for Neurofibromatoses Type II - Comparative Analysis 8
Neurofibromatoses Type II - Therapeutics under Development by Companies 9
Neurofibromatoses Type II - Therapeutics under Investigation by Universities/Institutes 10
Neurofibromatoses Type II - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Neurofibromatoses Type II - Products under Development by Companies 13
Neurofibromatoses Type II - Products under Investigation by Universities/Institutes 14
Neurofibromatoses Type II - Companies Involved in Therapeutics Development 15
Arno Therapeutics, Inc. 15
CalAsia Pharmaceuticals, Inc. 16
Lixte Biotechnology Holdings, Inc. 17
Novartis AG 18
Neurofibromatoses Type II - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 27
AR-42 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
everolimus - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
FRAX-597 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
LB-201 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
LB-205 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules to Inhibit Hsp90-Alpha and TRAP 1 for Neurofibromatosis Type 2 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Neurofibromatoses Type II - Recent Pipeline Updates 40
Neurofibromatoses Type II - Dormant Projects 47
Neurofibromatoses Type II - Product Development Milestones 48
Featured News & Press Releases 48
May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50
List of Tables
Number of Products under Development for Neurofibromatoses Type II, H1 2016 7
Number of Products under Development for Neurofibromatoses Type II - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Neurofibromatoses Type II - Pipeline by Arno Therapeutics, Inc., H1 2016 15
Neurofibromatoses Type II - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2016 16
Neurofibromatoses Type II - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016 17
Neurofibromatoses Type II - Pipeline by Novartis AG, H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 26
Neurofibromatoses Type II Therapeutics - Recent Pipeline Updates, H1 2016 40
Neurofibromatoses Type II - Dormant Projects, H1 2016 47
List of Figures
Number of Products under Development for Neurofibromatoses Type II, H1 2016 7
Number of Products under Development for Neurofibromatoses Type II - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Targets, H1 2016 20
Number of Products by Stage and Targets, H1 2016 20
Number of Products by Mechanism of Actions, H1 2016 22
Number of Products by Stage and Mechanism of Actions, H1 2016 22
Number of Products by Routes of Administration, H1 2016 24
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 24
Number of Products by Stage and Molecule Types, H1 2016 26
